• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

    10/8/25 8:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VNDA alert in real time by email

    Multiyear agreement includes exclusive Monumental Sports Network studio entitlement, activations across Capitals, Wizards, and Mystics, and deep integration via community and media platforms

    For photos of the new Vanda Pharmaceuticals Studio and video announcing the partnership, please CLICK HERE.

    WASHINGTON, Oct. 8, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE) today announced Vanda Pharmaceuticals (NASDAQ:VNDA), a leading global biopharmaceutical company headquartered in Washington, D.C., as the organization's newest Founding Partner for its next-generation arena in downtown Washington. A centerpiece of the agreement is Vanda's exclusive entitlement of the best-in-class Monumental Sports Network (MNMT) studio – now officially named the Vanda Pharmaceuticals Studio – home to pre- and post-game coverage, original content, and dynamic storytelling spanning MSE's full sports portfolio and more.

    Monumental Sports and Vanda Logos

    After signing on as the "marquee" jersey patch partner for the WNBA's Washington Mystics earlier this year, Vanda becomes the second Founding Partner of Monumental's transformative Capital One Arena project, joining United Airlines in supporting this world-class sports and entertainment destination. The multi-year, integrated partnership with MSE includes brand alignment with the NBA's Washington Wizards, NHL's Washington Capitals, Mystics, and extensive reach across MNMT – the company's award-winning regional media platform, setting new standards for local sports coverage.

    "This is a bold, future-facing partnership that reflects the shared ambition of Monumental and Vanda to tell bigger stories, reach wider audiences, and uplift the D.C. community," said Ted Leonsis, Founder, Chairman, Managing Partner, and CEO at MSE. "Vanda Pharmaceuticals is a hometown success story with a global footprint. As a Founding Partner and the entitlement sponsor of the Vanda Pharmaceuticals Studio, they will play a major role in shaping our media future, enhancing the fan experience, and powering this transformational development in downtown D.C."

    As MSE continues to redefine the regional sports media experience, a cornerstone of this partnership is Vanda's exclusive entitlement of the Vanda Pharmaceuticals Studio, the broadcast epicenter of MNMT. Opened in March 2024, the studio sits within MNMT's two-story, SMPTE 2110-certified facility, representing one of the most advanced regional media environments in the country. It features two fully equipped studios — with the ability to merge into a single national telecast-caliber set on non-conflict nights — powered by 24 cameras, 1,200 square feet of 4K LED displays, and cutting-edge robotics.

    As the named studio partner, Vanda will be prominently embedded in every layer of content produced by MNMT, from pre- and post-game shows to digital and longform storytelling. Distributed via cable, streaming, and social platforms across the DMV and beyond, MSE's media platform has rapidly grown into one of the most influential and innovative regional sports networks in the country, connecting with millions of fans each season.

    "As Vanda Pharmaceuticals is a Washington, D.C. headquartered company, we are honored to become an integral part of the 'Sports Capital' and help lead the exciting transformation of the sports and entertainment district in downtown Washington," said Mihael H. Polymeropoulos MD, CEO, President and Chairman of the Board of Vanda Pharmaceuticals. "This alliance with Monumental is a shared vision to promote growth and opportunity in the nation's capital, fostering innovation and community through sports, media, and shared experiences that bring people together."

    In addition to its entitlement of the Vanda Pharmaceuticals Studio, Vanda will be featured across multiple MSE platforms including:

    • Branding on-site and in broadcast across Capitals, Wizards, and Mystics games
    • Integrated in-game features and content on MNMT
    • Visibility across the Capital One Arena transformation and future arena assets
    • Ongoing support of local programming that reflects both Vanda and MSE's shared values around innovative community impact

    Vanda will have a prominent presence in the newly transformed Capital One Arena — an iconic sports and entertainment destination in the heart of the nation's capital that welcomes three million guests each year. Today's announcement comes as Phase One of construction nears completion in the next-generation arena. MSE is taking a 360-degree approach to reimagining the fan experience, with a focus on cutting-edge technology, immersive design, and community impact — creating a high-tech, high-touch venue built to inspire millions of annual visitors for the next 25 years.

    About Monumental Sports & Entertainment  

    Monumental Sports & Entertainment is one of America's leading integrated sports and entertainment companies and is ranked as one of the most valuable globally. Our people, players, teams, and events bring excitement and joy to millions. We invest and innovate to consistently raise the game so we can deliver extraordinary experiences that will inspire and unite our community, our fans, and our people. To learn more, please visit monumentalsports.com.  

    About Vanda Pharmaceuticals, Inc.  

    Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs to improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow them on X @vandapharma. 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/monumental-sports--entertainment-taps-dcs-own-vanda-pharmaceuticals-as-founding-partner-to-help-drive-the-creation-of-brand-new-downtown-arena-302577919.html

    SOURCE Monumental Sports & Entertainment

    Get the next $VNDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VNDA

    DatePrice TargetRatingAnalyst
    10/31/2024$18.00Buy
    H.C. Wainwright
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    2/25/2022$24.00 → $12.00Buy → Hold
    Jefferies
    More analyst ratings

    $VNDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    6/16/25 9:10:04 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    6/9/25 5:36:16 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

    Multiyear agreement includes exclusive Monumental Sports Network studio entitlement, activations across Capitals, Wizards, and Mystics, and deep integration via community and media platforms For photos of the new Vanda Pharmaceuticals Studio and video announcing the partnership, please CLICK HERE. WASHINGTON, Oct. 8, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE) today announced Vanda Pharmaceuticals (NASDAQ:VNDA), a leading global biopharmaceutical company headquartered in Washington, D.C., as the organization's newest Founding Partner for its next-generation arena in downtown Washington. A centerpiece of the agreement is Vanda's exclusive entitlement of the best-in-class Monu

    10/8/25 8:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

    WASHINGTON, Oct. 1, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has agreed on a collaborative framework with the U.S. Food and Drug Administration (FDA) for the resolution of certain disputes regarding HETLIOZ® (tasimelteon) and tradipitant. Key features of the agreement include: The FDA will conduct an expedited re-review of the partial clinical hold preventing long term clinical studies of tradipitant for the treatment of motion sickness by November 26, 2025. The FDA will continue its review of Vanda's New Drug Application (N

    10/1/25 5:02:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    5/21/25 9:23:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    5/19/25 5:13:38 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    SEC Filings

    View All

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    10/1/25 5:10:10 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

    10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    7/31/25 8:57:58 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    7/31/25 7:34:48 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

    H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    10/31/24 6:31:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00

    7/11/24 7:49:37 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals downgraded by Jefferies with a new price target

    Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously

    2/25/22 4:56:52 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Leadership Updates

    Live Leadership Updates

    View All

    Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

    WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin

    3/17/23 7:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, July 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025.

    7/31/25 7:30:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

    Conference Call and Webcast to Follow WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2025 on Thursday, July 31, 2025, before the market opens.  Vanda will host a conference call at 8:00 AM ET on Thursday, July 31, 2025, during which management will discuss the second quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9430387. The conf

    7/23/25 4:45:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/13/24 5:16:07 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/13/24 10:53:14 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/9/24 9:59:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care